ClinicalTrials.Veeva

Menu

Identification of the Cranberry Juice Compounds That Prevent Urinary Tract Infections

National Institutes of Health (NIH) logo

National Institutes of Health (NIH)

Status

Completed

Conditions

Urinary Tract Infections

Treatments

Drug: Cranberry juice cocktail

Study type

Interventional

Funder types

NIH

Identifiers

NCT00087828
F31 AT000623-1

Details and patient eligibility

About

The purpose of this study is to identify the substances in cranberry juice that make it effective in reducing urinary tract infections (UTIs) in women.

Full description

Urinary tract infections (UTIs) are a significant health issue, with one fourth of all women experiencing symptoms during their lifetimes. Cranberry juice has been shown to reduce the incidence of UTIs by preventing bacteria from adhering to the bladder. However, the compounds that direct this activity have not been identified. This study will identify and examine UTI-reducing compounds in cranberry juice.

Participants in this study will drink a specified amount of water following an overnight fast. Their urine will be collected 1 to 3 hours after the water is consumed. Several days later, the women will be provided with cranberry juice to replace the water in the regimen. Urine samples will be analyzed for compounds that have antibacterial or antiadhesion activity against the bacteria that cause UTIs.

Sex

Female

Ages

18 to 64 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Good overall health

Exclusion criteria

  • History of urinary tract infections
  • Use of cranberry products or antibiotics within 1 week of study start
  • Current use of any other medication
  • Hypertension
  • Diabetes
  • Pregnancy

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems